Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide (AC) versus docetaxel plus cyclophosphamide (TC)

• In: Pharmacoepidemiology/Pharmacoeconomics - Posters
• At: Istanbul (Turkey) (2009)
• Type: Poster
• Poster code: PP-P-014
• By: PENG, Liubao (Department of pharmacy, the Second Xiangya Hospital of Central South University, Changsha, China)
• Co-author(s): Wan, Xiaomin (Department of pharmacy, the Second Xiangya Hospital of Central South University, CHANGSHA, China)
  Tan, Chongqing (Department of pharmacy, the Second Xiangya Hospital of Central South University, CHANGSHA, China)
  Jon, Karnon (Department of Public Health, University of Adelaide, ADELAIDE, Australia)
  Chen, Gannong (Department of pharmacy, the Second Xiangya Hospital of Central South University, CHANGSHA, China)
  Li, Jianhe (Department of pharmacy, the Second Xiangya Hospital of Central South University, CHANGSHA, China)
  Cui, Wei (Department of pharmacy, the Second Xiangya Hospital of Central South University, CHANGSHA, China)
  Luo, Xia (Department of pharmacy, the Second Xiangya Hospital of Central South University, CHANGSHA, China)
  Cao, Junhua (Department of pharmacy, the Second Xiangya Hospital of Central South University, CHANGSHA, China)
  
• Abstract:

  Background: Over the past decades, the incidence of female breast cancer has risen not only in western countries, but also in China. New treatment options, however, place a heavy financial burden on patients and even on governments. An Oncology trial compared four cycles of doxorubicin/cyclophosphamide (AC) with four cycles of

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login